Cardiology Xagena
Study treatments for the ACTIVE W trial of the ACTIVE ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) program have been discontinued due to a significant di ...
Heightened platelet activity plays a critical role in thrombus formation, which is central to acute coronary syndromes ( ACS ), including non-ST-segment elevation ( NSTE )-ACS ( comprising unstable an ...
A randomised multicentre open-label study was evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy ...
Drug-eluting stents with durable biocompatible or biodegradable polymers have been developed to address the risk of thrombosis associated with first-generation drug-eluting stents.The aim of a study w ...
Bioabsorbable vascular scaffolds were developed to overcome limitations of permanent bare-metal or drug-eluting coronary stents, ie, stent thrombosis ( despite prolonged dual antiplatelet therapy ), t ...
Dual antiplatelet therapy ( DAPT ) cessation increases the risk of adverse events after percutaneous coronary intervention ( PCI ). Whether risk changes over time, depends on the underlying reason for ...
Dual antiplatelet therapy has become the cornerstone of the treatment of patients undergoing coronary stenting and of those with acute coronary syndromes with or without stent implantation. Although ...
The European Society of Cardiology ( ESC ) has published a position paper on the topic of triple therapy that shows great similarity to North American recommendations: diminished intensity of anticoag ...
Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. Patients were enrolled aft ...
Patients with a high-risk Paclitaxel drug-eluting stent who were given the shorter-acting antiplatelet drug Cilostazol ( Pletal ) prior to a surgical procedure safely transitioned off of dual antiplat ...
The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. Researchers have investigated the efficacy and safety of Ticagrelor ( Brili ...
A sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of Ticagrelor ( Brilinta, Brilique ) in reducing atherothrombotic events in post-myocardial infarction patients, based on the time fro ...
ESC Guidelines recommended for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention ( PCI ) in patients with acute coronary syndromes ( ACS ). The ...
The landmark Dual Antiplatelet Therapy ( DAPT ) trial revealed an impressive reduction of stent thrombosis and myocardial infarction after prolonged 30-month DAPT compared to the conventional 12-month ...
The combination of Ticagrelor ( Brilique ) and Aspirin ( Acetylsalicylic acid ) reduces ischaemic events compared with Aspirin alone in patients with stable coronary artery disease and diabetes. The ...
